Document is current
Any future updates will be listed below
-
Authors
Nguyen, Lien D https://orcid.org/0000-0001-8096-1570
Ehrlich, Barbara E https://orcid.org/0000-0001-9657-9704
-
Funding
Funding for this research was provided by:
HHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (P01DK057751)
- License Information
-
More Information
Article History
Received: 24 January 2020
Revised: 9 March 2020
Accepted: 1 April 2020
First Online: 29 April 2020
Conflict of interest
: B.E.E is a founder of Osmol Therapeutics, a company that is targeting neuronal calcium sensor 1 for therapeutic purposes, including chemotherapy‐induced neuropathy.
